JP2007525183A - 癌の処置および検出において有用な１０９ｐ１ｄ４と称される、核酸および対応タンパク質 - Google Patents

癌の処置および検出において有用な１０９ｐ１ｄ４と称される、核酸および対応タンパク質 Download PDF

Info

Publication number
JP2007525183A
JP2007525183A JP2006514206A JP2006514206A JP2007525183A JP 2007525183 A JP2007525183 A JP 2007525183A JP 2006514206 A JP2006514206 A JP 2006514206A JP 2006514206 A JP2006514206 A JP 2006514206A JP 2007525183 A JP2007525183 A JP 2007525183A
Authority
JP
Japan
Prior art keywords
protein
cell
antibody
cancer
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006514206A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007525183A5 (enExample
Inventor
アーサー ビー． ライターノ，
ピア エム． シャリタ−エイド，
ワンマオ ゲ，
ホアン ジェイ． ペレス−ビラー，
スティーブン ビー． カナー，
アヤ ヤコボヴィツ，
Original Assignee
アジェンシス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アジェンシス， インコーポレイテッド filed Critical アジェンシス， インコーポレイテッド
Publication of JP2007525183A publication Critical patent/JP2007525183A/ja
Publication of JP2007525183A5 publication Critical patent/JP2007525183A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2006514206A 2003-04-30 2004-04-30 癌の処置および検出において有用な１０９ｐ１ｄ４と称される、核酸および対応タンパク質 Pending JP2007525183A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46700203P 2003-04-30 2003-04-30
PCT/US2004/013568 WO2004098515A2 (en) 2003-04-30 2004-04-30 Nucleic acids and corresponding proteins entitled 109p1d4 useful in treatment and detection of cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011023063A Division JP2011152132A (ja) 2003-04-30 2011-02-04 癌の処置および検出において有用な１０９ｐ１ｄ４と称される、核酸および対応タンパク質

Publications (2)

Publication Number Publication Date
JP2007525183A true JP2007525183A (ja) 2007-09-06
JP2007525183A5 JP2007525183A5 (enExample) 2007-10-18

Family

ID=33435005

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2006514206A Pending JP2007525183A (ja) 2003-04-30 2004-04-30 癌の処置および検出において有用な１０９ｐ１ｄ４と称される、核酸および対応タンパク質
JP2011023063A Pending JP2011152132A (ja) 2003-04-30 2011-02-04 癌の処置および検出において有用な１０９ｐ１ｄ４と称される、核酸および対応タンパク質

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2011023063A Pending JP2011152132A (ja) 2003-04-30 2011-02-04 癌の処置および検出において有用な１０９ｐ１ｄ４と称される、核酸および対応タンパク質

Country Status (5)

Country Link
EP (1) EP1622571A4 (enExample)
JP (2) JP2007525183A (enExample)
AU (2) AU2004235755A1 (enExample)
CA (1) CA2522994C (enExample)
WO (1) WO2004098515A2 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7117033B2 (en) 2000-05-08 2006-10-03 Brainsgate, Ltd. Stimulation for acute conditions
US7561919B2 (en) 2002-11-14 2009-07-14 Brainsgate Ltd. SPG stimulation via the greater palatine canal
US8010189B2 (en) 2004-02-20 2011-08-30 Brainsgate Ltd. SPG stimulation for treating complications of subarachnoid hemorrhage
US9233245B2 (en) 2004-02-20 2016-01-12 Brainsgate Ltd. SPG stimulation
US8055347B2 (en) 2005-08-19 2011-11-08 Brainsgate Ltd. Stimulation for treating brain events and other conditions
US20070248535A1 (en) * 2005-02-07 2007-10-25 The Trustees Of Columbia University In The City Of New York Methods to treat or prevent hormone-resistant prostate cancer using siRNA specific for protocadherin-PC, or other inhibitors of protocadherin-PC expression or activity
KR101362681B1 (ko) * 2006-03-31 2014-02-13 알닐람 파마슈티칼스 인코포레이티드 Ｅｇ5 유전자의 발현을 억제하는 조성물 및 억제 방법
JP6236948B2 (ja) * 2013-07-17 2017-11-29 東ソー株式会社 抗体精製用溶出液および当該溶出液を用いた抗体精製方法
US9675796B2 (en) 2013-11-10 2017-06-13 Brainsgate Ltd. Implant and delivery system for neural stimulator
US11497767B2 (en) 2015-02-18 2022-11-15 Enlivex Therapeutics R&D Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11512289B2 (en) 2015-02-18 2022-11-29 Enlivex Therapeutics Rdo Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11000548B2 (en) 2015-02-18 2021-05-11 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11304976B2 (en) 2015-02-18 2022-04-19 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11318163B2 (en) 2015-02-18 2022-05-03 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11596652B2 (en) 2015-02-18 2023-03-07 Enlivex Therapeutics R&D Ltd Early apoptotic cells for use in treating sepsis
US10857181B2 (en) 2015-04-21 2020-12-08 Enlivex Therapeutics Ltd Therapeutic pooled blood apoptotic cell preparations and uses thereof
US10271907B2 (en) 2015-05-13 2019-04-30 Brainsgate Ltd. Implant and delivery system for neural stimulator
CA3014885A1 (en) 2016-02-18 2017-08-24 Enlivex Therapeutics Ltd. Combination immune therapy and cytokine control therapy for cancer treatment
TWI795381B (zh) 2016-12-21 2023-03-11 比利時商健生藥品公司 作為ｍａｌｔ１抑制劑之吡唑衍生物
ES2966132T3 (es) 2019-02-22 2024-04-18 Janssen Pharmaceutica Nv Forma cristalina de monohidrato de 1-(1-oxo-1,2-dihidroisoquinolin-5-il)-5-(trifluorometil)-(2-(trifluorometil)piridin-4-il)- 1h-pirazol-4-carboxamida
BR112021019799A2 (pt) 2019-04-11 2021-12-07 Janssen Pharmaceutica Nv Derivados contendo anéis de piridina como inibidores de malt1

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002083921A2 (en) * 2001-04-10 2002-10-24 Agensys, Inc. Nuleic acids and corresponding proteins useful in the detection and treatment of various cancers

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001234944A1 (en) * 2000-02-03 2001-08-14 Hyseq, Inc. Novel nucleic acids and polypeptides

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002083921A2 (en) * 2001-04-10 2002-10-24 Agensys, Inc. Nuleic acids and corresponding proteins useful in the detection and treatment of various cancers

Also Published As

Publication number Publication date
WO2004098515A3 (en) 2009-04-30
AU2004235755A1 (en) 2004-11-18
EP1622571A4 (en) 2012-05-02
AU2008212020A1 (en) 2008-09-25
CA2522994A1 (en) 2004-11-18
EP1622571A2 (en) 2006-02-08
CA2522994C (en) 2012-09-25
AU2008212020B2 (en) 2012-05-24
WO2004098515A2 (en) 2004-11-18
JP2011152132A (ja) 2011-08-11

Similar Documents

Publication Publication Date Title
JP4490502B2 (ja) 癌の処置および検出において有用な２８２ｐ１ｇ３と称される、核酸および対応タンパク質
JP4177877B2 (ja) 癌の処置および検出において有用な１６１ｐ２ｆ１０ｂと称される、核酸および対応タンパク質
JP5787487B2 (ja) 癌の処置および検出において有用なｓｔｅａｐ−１と名称が与えられる核酸および対応するタンパク質
US8853364B2 (en) Prostate stem cell antigen (PSCA) variants and subsequences thereof
JP4299872B2 (ja) 癌の処置および検出において有用な１６１ｐ２ｆ１０ｂと称される、核酸および対応タンパク質
JP2011152132A (ja) 癌の処置および検出において有用な１０９ｐ１ｄ４と称される、核酸および対応タンパク質
US7968090B2 (en) Nucleic acids and corresponding proteins entitled 191P4D12(b) useful in treatment and detection of cancer
JP2005534287A (ja) 癌の処置および検出において有用な９８ｐ４ｂ６との名称の核酸および対応するタンパク質
JP2010110325A (ja) 癌の処置および検出において有用な１９３ｐ１ｅ１ｂと称される、核酸および対応タンパク質
US20110086437A1 (en) Methods to inhibit cell growth
US7811575B2 (en) Nucleic acids and corresponding proteins entitled 158P3D2 useful in treatment and detection of cancer
US7842458B2 (en) Nucleic acids and corresponding proteins entitled 58P1D12 useful in treatment and detection of cancer
JP2008509700A (ja) 癌の処置および検出において有用な５８ｐ１ｄ１２と称される核酸および対応するタンパク質
CA2588564A1 (en) Nucleic acids and corresponding proteins entitled 158p3d2 useful in treatment and detection of cancer
JP5840351B2 (ja) 癌の処置および検出において有用な９８ｐ４ｂ６と称される、核酸および対応タンパク質
JP2006508163A (ja) 癌の処置および検出において有用な２４ｐ４ｃ１２と称される、核酸および対応タンパク質
JP5122592B2 (ja) 癌の処置および検出において有用な２４ｐ４ｃ１２と称される、核酸および対応タンパク質
JP2005537797A (ja) 癌の処置および検出において有用な９８ｐ４ｂ６と称される、核酸および対応タンパク質

Legal Events

Date Code Title Description
RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20080314

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20080527

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100309

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100602

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100609

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100707

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100714

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100806

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100813

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100902

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20101005

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110204